REG - Citigroup Global Mkt Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI)
RNS Number : 5149MCitigroup Global Markets Limited08 January 2019
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH
RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader:
Citigroup Global Markets Limited
(b) Name of offeror/offeree in relation to whose
relevant securities this form relates:
Use a separate form for each offeror/offereeTakeda Pharmaceutical Company Limited
(c) Name of the party to the offer with which exempt
principal trader is connected:Shire plc
(d) Date dealing undertaken:
7 January 2019
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
If it is a cash offer or possible cash offer, state "N/A"YES
Shire plc
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchases/ sales
Total number of securities
Highest price per unit paid/received
Lowest price per unit paid/received
Ordinary
Purchase
98,900
USD 37.2664
USD 36.9136
Ordinary
Purchase
3,692,110
JPY 4038.0000
JPY 0.0000
Ordinary
Sale
51,500
USD 37.1690
USD 37.1690
Ordinary
Sale
974,300
JPY 4038.0000
JPY 3968.0837
ADS
Purchase
1,000
USD 18.5100
USD 18.5100
ADS
Sale
1,000
USD 18.5100
USD 18.5100
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFDNature of dealing
e.g. opening/closing a
long/short position,
increasing/reducing a
long/short positionNumber of reference securities
Price per unit
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description
e.g. call optionWriting, purchasing,
selling,
varying etc.Number of securities to
which option relatesExercise price per unit
Type
e.g. American,
European etc.Expiry date
Option money paid/ received per unit
(ii) Exercise
Class of relevant security
Product description
e.g. call optionExercising/ exercised against
Number of
securitiesExercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversionDetails
Price per unit
(if applicable)
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding,
formal or informal, relating to relevant securities which may be an inducement to deal
or refrain from dealing entered into by the exempt principal trader making the
disclosure and any party to the offer or any person acting in concert with
a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between
the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
Date of disclosure:
8 January 2019
Contact name:
Connor McLaughlin
Telephone number:
02895 955 328
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information
Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDFERDMGGMGRNGLZM
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement